TAIM
BMY.RT

Te Ahumairangi Investment Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Te Ahumairangi Investment Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-55,200
Closed -$38K – 121
2020
Q4 		$38K Sell
55,200
-171,877
-76% -$366K 0.01% 117
2020
Q3 		$511K Buy
+227,077
New +$648K 0.09% 112

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Te Ahumairangi Investment Management's BMY.RT Position: Q1 2021 in Review

Te Ahumairangi Investment Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 55,200 shares — an estimated $38K sold.

Te Ahumairangi Investment Management first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $511K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Te Ahumairangi Investment Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Te Ahumairangi Investment Management sold 55,200 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $38K.
  • Te Ahumairangi Investment Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Te Ahumairangi Investment Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $511K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Te Ahumairangi Investment Management's 13F filing for Q1 2021, filed 14 May 2021.